| Aug 30 |
Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?
|
| Aug 29 |
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
|
| Aug 28 |
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 23 |
Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound?
|
| Aug 23 |
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
|
| Aug 23 |
Alkermes launches Phase II trial of ALKS 2680 for narcolepsy type 2
|
| Aug 22 |
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
|
| Aug 22 |
We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease
|
| Aug 20 |
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
|
| Aug 19 |
Here's Why Alkermes (ALKS) is a Strong Value Stock
|
